Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VANTAGE: Volixibat for Cholestatic Pruritus in Primary Biliary Cholangitis
2023-504660-41-00Phase 2Authorised
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Volixibat with Placebo (2 arms). Planned start Aug 2023; status: authorised.
02
Drugs
volixibat
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2023-504660-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504660-41-00.